

DETAILED ACTION

1. Applicant's amendment to the claims, filed on December 13, 2010, is entered.

Claims 8-11 have been canceled.

Claims 1-7 and 12-37 are pending.

In view of applicant's cancelation of claims 8-11 (drawn to SEQ ID NOs) and upon further consideration, the previous species election requirement (SEQ ID NOs, specific effector molecules, and specific Cysteine positions) set forth on pages 3-4 of the Office Action (mailed on May 27, 2009) has been withdrawn.

2. Applicant's IDS, filed on December 13, 2010, is considered.

EXAMINER'S AMENDMENT

3. An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to Applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the Issue Fee.

4. Authorization for this Examiner's Amendment was given in a telephone interview with applicant's representative Sandra B. Weiss on January 14, 2011.

In the Claims:

5. Claims 18-25 and 28-36 have been canceled.
6. In claim 26, the word "Fab" in line 2 has been replaced with ---the Fab---.

7. In claim 27, the word "Fab" in line 2 has been replaced with ---the Fab---
8. Claims 1-7, 12-17, 26, 27, and 37 are allowed.

REASONS FOR ALLOWANCE

9. The following is an Examiner's Statement of Reasons for Allowance:

The Examiner's Amendment set forth supra, in conjunction with Applicant's amendment filed on December 13, 2010 has obviated the previous rejections of record set forth in the Office Action mailed on March 23, 2010.

Applicant asserts that the Fab or Fab' taught by the prior art, the cysteines that form the heavy-light chain bond are not at the ends of either the light chain or the heavy chain (see Engineered monoclonal antibody.svg on IDS filed on December 13, 2010), whereas the instant invention is drawn to an antibody Fab fragment comprising a heavy chain constant region that terminates at the interchain cysteine of C_H1.

Accordingly, the claims 1-7, 12-17, 26, 27, and 37 are deemed allowable.

10. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."
11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chun Dahle whose telephone number is 571-272-8142. The examiner can normally be reached on 8:30-5:00. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor Ram Shukla can be reached 571-272-0735. The fax

phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Chun Dahle/

Primary Examiner, Art Unit 1644